Forward focused thinking
Blue Latitude Health’s consultancy is based on a rich vein of expert knowledge. Here you’ll find thought-provoking commentary, articles, and downloadable resources created by our consultants.
Explore our ideas and get a deeper understanding of the current and future trends in healthcare:
Filter articles
Are we harnessing the full emotional power of brand creativity?
|30th September 2016
Creative Director Damien Parsonage breaks down the common misconception that pharma and healthcare marketing for healthcare professionals ought to be entirely scientific and rational. Brands are powerful; here's how to strengthen yours by infusing it with emotion.
Artificial Intelligence: the new healthcare algorithm
|26th September 2016
The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare. Associate Medical Copywriter Kulveer Singh dives deeper into the technology.
Marketing strategy in complex environments
|19th September 2016
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.
DAM and CMS: managing assets to maximise adoption and value
|14th September 2016
Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised to maximise outcomes for pharma and agencies.
Is fear an effective driver of behaviour change?
|4th September 2016
Client Lead Natalie Seebeck explains that applying fear-based models in communications can be effective, if the right components are used in the right way.
Alzheimer’s disease: reviewing the immediate treatment horizon
|2nd September 2016
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.
A stumble, but not a fall – what’s next for Opdivo?
|24th August 2016
In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems.
Immuno-oncology; bringing patients closer to treatment
|18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.
The biofuel cell – breathing new life into portable electronics?
|16th August 2016
Associate Medical Copywriter Kulveer Singh explains how biofuel cells work, why they are an exciting alternative to normal battery power, and what the challenges are in implementing their use.
Products as portfolios: positioning immuno-oncology products
|8th August 2016
The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning in this situation is vital to cut through the noise, so we've outlined some key learnings from our extensive experience in this area.
Previous
